Neurocrine Biosciences (NASDAQ: NBIX) reported Q2 EPS of $2.85, $1.27 better than the analyst estimate of $1.58. Revenue for the quarter came in at $959 million versus the consensus estimate of $877.34 million.

GUIDANCE:

Neurocrine Biosciences sees FY2026 revenue of $2.82-2.87 billion, versus the consensus of $3.79 billion.

For earnings history and earnings-related data on Neurocrine Biosciences (NBIX) click here.